BMLBMLKF 69 Net Margin % is 3.33% as of Mar. 2026, which is 37% below its 10-year median of 5.32. GuruFocus rates BMLKF with a GF Score™ of 69/100 and a GF Value™ of $26.78. The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, BML ranks better than 64.22% on this metric.
Net margin is calculated as Net Income divided by its Revenue. BML's Net Income for the
three
months ended in Mar. 2026 was $7.5 Mil. BML's Revenue for the
three
months ended in Mar. 2026 was $225.5 Mil. Therefore, BML's net margin for the quarter that ended in Mar. 2026 was 3.33%.
The historical rank and industry rank for BML's Net Margin % or its related term are showing as below:
BMLKF'
s Net Margin % Range Over the Past 10 Years
Min: 4.37 Med: 5.32 Max: 18.13
Current: 5.16
BMLKF's Net Margin % is ranked better than 64.22% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs BMLKF: 5.16
BML (OTCPK:BMLKF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BML Net Margin % Related Terms
BML Net Margin % Historical Data
* Premium members only.
The historical data trend for BML's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BML's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BML Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BML's Net Margin % distribution charts can be found below:
* The bar in red indicates where BML's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BML (BMLKF) has a Net Margin % of 3.33% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on BML and its competitors. This is 37% below median its historical median of 5.32. Over the past decade, BML's Net Margin % has ranged from 4.37 to 18.13. According to the industry distribution chart, BML ranks #73 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 35.8%.
Is BML's Net Margin % too high?
BML's current Net Margin % of 3.33% is 37% below median its 10-year median of 5.32. Over the past 10 years, this metric has ranged from a low of 4.37 to a high of 18.13. Based on the distribution chart, BML ranks #73 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BML has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does BML's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BML ranks #73 out of 204 companies for Net Margin %. This puts BML in the upper half of its industry. Historically, BML's own Net Margin % has ranged from 4.37 to 18.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BML and its competitors. BML's current Net Margin % is 3.33%, which is 37% below median its own 10-year median of 5.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BML stock overvalued right now?
BML (BMLKF) has a current Net Margin % of 3.33%. The stock's GF Value™ is $26.78, compared to a current price of $25.21 — trading 5.9% below its estimated fair value. The current Net Margin % is 3.33%, which is 37% below median its 10-year median of 5.32. BML's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BML (BMLKF), the current Net Margin % is 3.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BML (BMLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BML stock appears to be undervalued.
The current stock price of $25.21 is trading 5.9% below its estimated GF Value™ of $26.78.
Key valuation signals for BMLKF:
Net Margin %: 3.33% (37% below median its 10-year median of 5.32)
GF Value™: $26.78 vs. price of $25.21 (5.9% below fair value)
No single metric tells the full story. See the BMLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.
69GF Score
Get the complete analysis for BMLKF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMLKF has been successfully added to your 
